During the corresponding time, Axsome Therapeutics Inc recorded a revenue increase by 45.54 % year on year, sequentially revenue grew by 14.21 %. While revenue at the Axsome Therapeutics Inc 's corporate clients
Axsome Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers and market segments including Medicare Advantage and Medicaid managed care plan enrollees, physicians, teaching hospitals, physician assistants, nurse practitioners, other mid-level practitioners, and health care providers (HCPs). Its operations are subject to regulatory requirements affecting marketing and payments to these groups, including reporting obligations under the Sunshine Act for manufacturers of covered drugs under Medicare, Medicaid, and the State Children’s Health Insurance Program. The company’s business arrangements also include patient assistance programs and customer incentive programs.
Axsome Therapeutics Expands Its Clinical Trials for Solriamfetol, a Potential Breakthrough in CNS Disorder TreatmentsIn two recent announcements, Axsome Therapeutics, a leading biopharmaceutical company specializing in the development of therapies for central nervous system (CNS) disorders, has initiated Phase 3 trials for solriamfetol, a promising investigational treatment for binge eating disorder (BED) and major depressive disorder (MDD) in adults. These significant developments mark a milestone in the company s efforts to address unmet medical needs and improve the quality of life for patients suffering from these conditions.The ENGAGE Phase 3 trial for solriamfetol targeting binge eating disorder (BED) ...
Axsome Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers and market segments including Medicare Advantage and Medicaid managed care plan enrollees, physicians, teaching hospitals, physician assistants, nurse practitioners, other mid-level practitioners, and health care providers (HCPs). Its operations are subject to regulatory requirements affecting marketing and payments to these groups, including reporting obligations under the Sunshine Act for manufacturers of covered drugs under Medicare, Medicaid, and the State Children’s Health Insurance Program. The company’s business arrangements also include patient assistance programs and customer incentive programs.
Sources:
Axsome Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Axsome Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Axsome Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
185.81 %